Indegene Share Price

NSE
599.75
+0.90 (0.17%)
INDGN • 13 Jun, 2025 | 03:29 PM
BUY
The current prices are delayed, login or Open Demat Account for live prices.
Indegene Stock Performance
Today’s Low - High
583.35
610.35
583.35
610.35
52 Week Low - High
499.00
736.30
499.00
736.30

Open

589.00

Prev. Close

598.85

Total Traded Value

190.53 Cr

View details of Market Depth
Indegene Fundamental

Market Cap (in crs)

14,386.08

Face Value

2

Turnover (in lacs)

19,052.77

Key Metrics
Qtr Change %
16.7
Dividend yield 1yr %
Below industry Median
0.3

Indegene Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Indegene Quarterly Revenue

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
755.6 Cr
720.4 Cr
686.8 Cr
676.5 Cr
673 Cr

Indegene Yearly Revenue

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
2946.5 Cr
2665.9 Cr
2364.1 Cr
1690.5 Cr
996.92 Cr

Indegene Quarterly Net Profit/Loss

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
117.6 Cr
109.7 Cr
91.7 Cr
87.7 Cr
94.8 Cr

Indegene Yearly Net Profit/Loss

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
406.7 Cr
336.7 Cr
266.1 Cr
162.82 Cr
185.88 Cr
Indegene Result Highlights
  • Indegene Ltd reported a 8.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.

  • Its expenses for the quarter were down by 7.6% QoQ and - - YoY.

  • The net profit decreased 13.6% QoQ and - - YoY.

  • The earnings per share (EPS) of Indegene Ltd stood at 4.2 during Q4FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Indegene shareholding Pattern

Foreign Institutions
5.2%
Mutual Funds
2.6%
Domestic Institutions
5%
Public
89.8%
Foreign Institutions
5%
Mutual Funds
1.6%
Domestic Institutions
4%
Public
91%
Foreign Institutions
4.8%
Mutual Funds
1.6%
Domestic Institutions
3.2%
Public
92%
Foreign Institutions
3.8%
Mutual Funds
2.3%
Domestic Institutions
3.8%
Public
92.4%

Indegene Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
599.75
Current Price
Bullish Moving Averages
15
Bearish Moving Averages
1
5Day EMA
597.40
10Day EMA
596.50
12Day EMA
596.20
20Day EMA
593.50
26Day EMA
591.00
50Day EMA
584.00
100Day EMA
584.00
200Day EMA
589.30
5Day SMA
595.80
10Day SMA
597.20
20Day SMA
598.30
30Day SMA
588.50
50Day SMA
578.80
100Day SMA
577.50
150Day SMA
594.50
200Day SMA
610.10
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
2335860 Rs
3210321 Rs
Week Rs
1008527 Rs
1810487 Rs
Month Rs
1818854 Rs
2969317 Rs
Resistance & Support
597.65
Pivot
Resistance
First Resistance
611.95
Second Resistance
624.65
Third Resistance
638.95
Support
First Support
584.95
Second support
570.65
Third Support
557.95
Relative Strength Index
53.25
Money Flow Index
19.08
MACD
5.16
MACD Signal
6.52
Average True Range
21.51
Average Directional Index
19.04
Rate of Change (21)
-1.72
Rate of Change (125)
1.41
Shareholding
Name
Holding Percent
Sbi Innovative Opportunities Fund
1.39
Fidelity Funds - India Focus Fund
1.75
Smallcap World Fund, Inc
1.19

Indegene Latest News

09 JUN 2025 | Monday

Indegene Ltd - 544172 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

06 JUN 2025 | Friday

Indegene Ltd - 544172 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

05 JUN 2025 | Thursday

Indegene Ltd - 544172 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

View More

Indegene Company background

Founded in: 1998
Indegene Limited was incorporated as Indegene Lifesystems Private Limited at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to Indegene Private Limited and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to Indegene Limited on November 17, 2022.The Company is a global provider of solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and healthcare organizations. It provide digitalled commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a digital first approach for optimizing the lastmile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients.Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analyticsin helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals.In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies. In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited.On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021.The Company acquired Cult Health, a fullservice healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022.The Company launched Invisage, an AIenabled hybrid omnichannel sales and marketing platform in 2023. The Company made a public issue of 40,766,550 Equity Shares of face value of Rs 2 each by raising funds aggregating to Rs. 1842 Crore comprising a fresh issue of 16,833,818 Equity Shares aggregating to Rs. 760 Crore and 23,932,732 Equity Shares aggregating to Rs 1082 Crore through Offer for Sale in May, 2024.In 2024, the Company acquired a controlling stake in Trilogy Writing Consulting GmbH.

As of 13 Jun, 2025, INDGN share price is ₹599.2. The stock opened at ₹589 and had closed at ₹598.8 the previous day. During today’s trading session, INDGN share price moved between ₹583.35 and ₹610.35, with an average price for the day of ₹596.50. Over the last 52 weeks, the stock has recorded a low of ₹499.00 and a high of ₹736.30. In terms of performance, INDGN share price has increased by 1.6% over the past six months and has declined by 0.22% over the last year.

Read More

Indegene FAQs

Indegene share price is ₹599.75 in NSE and ₹599 in BSE as on 13/6/2025.

Indegene share price in the past 1-year return was -0.14. The Indegene share hit a 1-year low of Rs. 499 and a 1-year high of Rs. 736.3.

The market cap of Indegene is Rs. 14386.08 Cr. as of 13/6/2025.

The PE ratios of Indegene is 80.52 as of 13/6/2025.

The PB ratios of Indegene is 7.61 as of 13/6/2025

The Mutual Fund Shareholding in Indegene was 2.65% at the end of 13/6/2025.

You can easily buy Indegene shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Indegene stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

Open Demat Account
+91 -